Skip to main content
. 2025 Mar 11;11:e53539. doi: 10.2196/53539

Table 2.

Breast cancer trial multivariate regression analysis of predictors for acute healthcare visits for chemotherapy-related symptoms


 Intervention group (n=74) Control group (n=75) B SE Standardized coefficient [Exp(B)] 95% CI P value χ2/dfa
Visits
Acute outpatient


Feverb M (SD) 0.46 (0.86) 0.28 (0.63) N/Ac N/A N/A N/A N/A N/A


Dependent variable: total, n 34 (n=13) 21 (n=9) N/A N/A N/A N/A N/A N/A


Independent variables: N/A N/A N/A N/A N/A N/A .49d 1.141

Groupe N/A N/A –0.46 0.33 0.63 0.331-1.202 .16f N/A


Age N/A N/A –0.01 0.02 0.992 0.949-1.037 .72f N/A


HRQOL N/A N/A –0.70 1.93 0.498 0.011-22.106 .72f N/A


Comorbidity N/A N/A 0.15 0.20 1.156 0.773-1.727 .48f N/A

NACTg N/A N/A –0.08 0.07 0.92 0.800-1.058 .24f N/A


Unplanned admissions M (SD) 0.50 (71) 0.39 (0.72) N/A N/A N/A N/A N/A N/A


Dependent variable: total, n 37 (n=7) 29 (n=6) N/A N/A N/A N/A N/A N/A


Independent variables N/A N/A N/A N/A N/A N/A .52d .877

Groupe N/A N/A –0.220 0.302 0.803 0.444-1.451 .47f N/A


Age N/A N/A 0.010 0.021 1.010 0.969-1.054 .62f N/A


HRQOL N/A N/A –3.048 1.760 0.047 0.002-1.494 .08f N/A

Comorbidity N/A N/A 0.029 0.193 1.030 0.705-1.504 .88f N/A

NACTg N/A N/A –0.036 0.061 0.965 0.857-1.086 .55f N/A
Acute inpatient

All M (SD) 0.73 (0.98) 0.60 (0.82) N/A N/A N/A N/A N/A N/A


Dependent variable: total, n 54 (n=35) 45 (n=32) N/A N/A N/A N/A N/A N/A

Independent variables: N/A N/A N/A N/A N/A N/A .72d .722

Groupe N/A N/A –0.182 0.2636 0.834 0.497-1.398 .49f N/A

Age N/A N/A 0.006 0.0187 1.006 0.969-1.043 .76f N/A

HRQOL N/A N/A –1.291 1.634 0.275 0.011-6.768 .43f N/A

Comorbidity N/A N/A 0.055 0.1702 1.057 0.757-1.476 .74f N/A

NACTg N/A N/A –0.068 0.0568 0.934 0.836-1.044 .23f N/A

Feverb M (SD) 0.39 (0.70) 0.32 (0.55) N/A N/A N/A N/A N/A N/A

Dependent variable: Total, n 29 (n=22) 24 (n=21) N/A N/A N/A N/A N/A N/A

Independent variables: N/A N/A N/A N/A N/A N/A .94d .838

Groupe N/A N/A –0.20 0.32 0.815 0.433-1.535 .53f N/A

Age N/A N/A 0.01 0.02 1.01 0.965-1.057 .66f N/A

HRQOL N/A N/A –1.04 1.94 0.353 0.008-15.75 .59f N/A

Comorbidity N/A N/A –0.13 0.23 0.876 0.557-1.378 .57f N/A

NACTg N/A N/A –0.01 0.07 0.988 0.868-1.124 .86f N/A

Gastroenteritisb M (SD) 0.08 (0.36) 0.16 (0.40) N/A N/A N/A N/A N/A N/A

Dependent variable: total, n 6 (n=4) 12 (n=11) N/A N/A N/A N/A N/A N/A

Independent variables: N/A N/A N/A N/A N/A N/A .77d 1.186

Groupe N/A N/A 0.66 0.53 1.931 0.686-5.440 .21f N/A

Age N/A N/A 0.02 0.04 1.019 0.944-1.100 .63f N/A

HRQOL N/A N/A 1.83 3.35 6.245 0.009-4422.840 .58f N/A

Comorbidity N/A N/A –0.31 0.41 0.737 0.328-1.657 .46f N/A

NACTg N/A N/A 0.004 0.100 1.004 0.826-1.220 .97f N/A

Anemiab M (SD) 0.05 (0.23) 0.05 (0.23) N/A N/A N/A N/A N/A N/A

Dependent variable: total, n 4 (n=4) 4 (n=4) N/A N/A N/A N/A N/A N/A

Independent variables: N/A N/A N/A N/A N/A N/A .73d .961

Groupe N/A N/A -0.10 0.74 0.901 0.210-3.863 .89f N/A

Age N/A N/A 0.10 0.07 1.101 0.963-1.258 .16f N/A

HRQOL N/A N/A 1.85 4.74 6.346 0.001-68734.141 .70f N/A

Comorbidity N/A N/A -0.94 0.73 0.389 0.093-1.633 .20f N/A

NACTg N/A N/A 0.03 0.14 0.029 0.780-1.357 .89f N/A

Urinary tract infectionb M (SD) 0.04 (0.20) 0.05 (0.03) N/A N/A N/A N/A N/A N/A

Dependent variable: total, n 3 (n=3) 4 (n=3) N/A N/A N/A N/A N/A N/A

Independent variables: N/A N/A N/A N/A N/A N/A .31d 1.268

Groupe N/A N/A –0.09 0.84 0.911 0.177-4.702 .91f N/A

Age N/A N/A 0.03 0.05 1.030 0.926-1.146 .58f N/A

HRQOL N/A N/A 4.01 6.39 55.11 0.000- 15250488 .53f N/A

Comorbidity N/A N/A 0.29 0.43 1.34 0.571-3.144 .50f N/A

NACTg N/A N/A 0.07 0.14 1.08 0.818-1.426 .59f N/A

aPearson χ2 value divided by degrees of freedom (goodness of fit of the model).

bNr of acute visits when a patient received the diagnose.

cN/A: not applicable.

dP value Omnibus test General Linear Model Negative Binomial Regression.

eIntervention/Control; Reference category=Intervention

fP value for the independent variable in the General Linear Model Negative Binomial Regression.

gNeoadjuvant chemotherapy treatments